07:00 , Sep 7, 2016 |  BC Extra  |  Company News

FDA recommends against ovarian cancer screening tests

FDA recommended against the use of screening tests for ovarian cancer. In a statement released Wednesday, the agency said there are no tests sensitive enough to "reliably" screen for ovarian cancer "without a high number...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

Cambridge Innovation Capital plc financial update

Cambridge Innovation Capital plc, Cambridge, U.K.   Business: Finance   Date announced: 2016-08-19   Note: Cambridge Innovation Capital raised L75 million ($97 million). The firm, which invests in technology and healthcare companies, plans to invest the funds in...
07:00 , Aug 19, 2016 |  BC Extra  |  Financial News

Cambridge Innovation raises L75M

Cambridge Innovation Capital plc raised L75 million ($97 million) in a private placement that included new investors Woodford Investment Management, Winton Ventures and the Oman Investment Fund. Existing shareholders including the University of Cambridge Endowment...
07:00 , May 25, 2015 |  BC Week In Review  |  Financial News

Abcodia completes venture financing

Abcodia Ltd., London, U.K.   Business: Diagnostic, Pharmacogenetics   Date completed: 2015-05-18   Type: Venture financing   Raised: L5.3 million ($8.2 million)   Investors: Cambridge Innovation Capital plc; Scottish Equity Partners; Albion Ventures; UCL Business plc   ...
08:00 , Nov 17, 2014 |  BioCentury  |  Tools & Techniques

Abcodia's (bio)bankroll

Abcodia Ltd. is hoping therapeutics companies will be able to pinpoint the very start of disease by using the biotech's massive, longitudinal biobank to find out exactly when levels of a marker or target in...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Abcodia, Massachusetts General Hospital deal

The hospital granted Abcodia exclusive, worldwide rights to commercialize the risk of ovarian cancer algorithm (ROCA). The diagnostic test compares a woman's pattern of CA-125 levels over time with the known profiles of women prior...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Abcodia, Cellmid deal

The companies partnered to validate midkine ( MDK; MK) as a biomarker for cancer diagnosis using Cellmid's MK-ELISA test. The deal covers testing of multiple cancer indications, but the partners will initially focus on...
07:00 , Jul 11, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Last month's public-private partnership with the highest total funding was the launch of the Global Health Innovative Technology Fund, an infectious disease initiative that plans to disperse $100 million over 5 years. On the biotech...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Abcodia, AIT Austrian Institute of Technology deal

Abcodia partnered with the institute to design a series of longitudinal studies to validate panels of biomarkers for the early detection of lung and colorectal cancers. Abcodia will provide its samples free of charge, and...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Abcodia, Cancer Research U.K. deal

Cancer Research U.K. and its Cancer Research Technology Ltd. (CRT) commercial arm partnered with Abcodia to develop blood tests to detect a range of cancers when they are still early stage and asymptomatic. Abcodia...